Skip to main content
NCBI home page
Nature Portfolio logoLink to Nature Portfolio
. 2023 Mar 9;615(7953):E23. doi: 10.1038/s41586-023-05892-1

Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma

Rodabe N Amaria 1,✉,#, Michael Postow 2,#, Elizabeth M Burton 1,#, Michael T Tetzlaff 3, Merrick I Ross 4, Carlos Torres-Cabala 5, Isabella C Glitza 1, Fei Duan 6, Denái R Milton 7, Klaus Busam 8, Lauren Simpson 1, Jennifer L McQuade 1, Michael K Wong 1, Jeffrey E Gershenwald 4, Jeffrey E Lee 4, Ryan P Goepfert 9, Emily Z Keung 4, Sarah B Fisher 4, Allison Betof-Warner 2, Alexander N Shoushtari 2, Margaret Callahan 2, Daniel Coit 10, Edmund K Bartlett 10, Danielle Bello 10, Parisa Momtaz 2, Courtney Nicholas 6, Aidi Gu 6, Xuejun Zhang 6, Brinda Rao Korivi 11, Madhavi Patnana 11, Sapna P Patel 1, Adi Diab 1, Anthony Lucci 4, Victor G Prieto 5, Michael A Davies 1, James P Allison 6, Padmanee Sharma 6, Jennifer A Wargo 4, Charlotte Ariyan 10, Hussein A Tawbi 1
PMCID: PMC10033416  PMID: 36894629

Correction to: Nature 10.1038/s41586-022-05368-8 Published online 26 October 2022

In the version of this article initially published, the surname of author Michael T. Tetzlaff was misspelled as ‘Tezlaff.’ In addition, the Acknowledgements section omitted mention of grant P50CA221703 from the National Cancer Institute of the National Institutes of Health, which supported the work. The errors have been corrected in the HTML and PDF versions of the article.

Articles from Nature are provided here courtesy of Nature Publishing Group

RESOURCES